Agastiya Biotech is not just another biotech or pharma company. The goal of Agastiya Biotech is to create toxicity-free drugs with maximum efficacy combined with affordable pricing for the global population. Agastiya seeks to accomplish this goal through its new discovery engine that combines ancient natural sciences with quantum biology.
The upcoming India-based Phase 1 clinical study of our AB001 molecule for multiple metastatic cancer patients is expected to bring breakthrough discovery in non-toxic cancer therapy with maximized efficacy in tumor regression. Dr. Pillai, along with his Chief Scientist, Dr. Dinesh have created over 40 small molecules for different indications. They are waiting to get into the labs for further research and clinical studies. Agastiya Biotech’s out-of-the box approach in drug discovery and treatment of diseases are unmet need of our day. Talking about his innovation Dr. Pillai says that his role in drug discovery is to excavate and resurrect what had been done millenniums ago and redeem the rigidity and linearity paradigms of western biotech.
Agastiya Biotech founder and inventor, Baskaran Pillai, PhD, is a visionary who synthesizes ancient natural sciences with modern quantum biology, medicinal chemistry, and string theories. Dr. Pillai’s innovative theories of de-mythologization, illustrated in his doctoral dissertation, led him to the merger of religion and science, which Albert Einstein had dreamed about in his One Theory of Everything and the Unified Theory. Dr. Pillai’s drug discoveries are based on several complex concepts such as the homology of neuro-theology and biology, the translational-transcriptional correspondence between quantum vibrations, intelligence, and Siddha pinda-anda (micro-macro) functional groups, and femto-biology. His drug discovery, like his brain mapping fMRI studies by Harvard scientists, is ahead of existing known frontiers in modern science. He has discovered dozens of novel small molecules belonging to a new drug platform with minimum toxicity and maximum efficacy, particularly in oncology. Not designed following high throughput, AI, combinatorial chemistry, and other similar discovery engines, Pillai’s molecules are a class by themselves targeting multiple diseases and target areas working at molecular as well as femto-levels.
Heading Agastiya Biotech’s cancer stem cell research, Dr. Dinesh holds a PhD in Stem Cell Biology from Sri Ramachandra University in Chennai. He has over 12 years in dedicated stem cell research and drug discovery with many premier institutions resulting in dozens of international and national publications and several patents. Dr. Dinesh conducted a single-arm, open-labeled clinical study with chronic plaque psoriasis patients, in which he also involved in dose preparation, safety, validation and efficacy studies, resulting in the launch of a chronic plaque psoriasis product sold to Lupin Pharmaceuticals.
Medical Advisory Team
Prof Dr Anitha Ramesh (Chandra)
MBBS ( Hons ) DCH ( UK) , MD , DNB , DM ( Medical Oncology), MNAMS, MSC Oncology (UK ) MBA ( Health Service Management ), PhD Trained in UK and USA in Oncology.
Dr. Anitha Ramesh has over 20 years of clinical experience in Oncology. She is currently Principal Investigator at Saveetha Medical College on Vopec Pharmaceuticals Phase 1 study of AB001 in India. She served as Principal Investigator on over 20 Phase 2 and 3 oncology drug candidates for multinational pharmaceutical companies.
Dr. Anitha is Professor and Head Medical Oncology Saveetha Medical College and Hospital in Chennai India. She serves as Senior Consultant Medical and Pediatric Oncology at Agastiya Biotech, USA, and Apollo Specialty Hospital and Kauvery HCG cancer centre in Chennai. She is Founder and Managing Trustee Freedom from Cancer Relief and Research Foundation “A public trust for Cancer in Developing countries”.
Dr. Anitha has received national and international recognition including: “Golden Women in Medicine” and “South Indian Women Achiever’s Award” in 2020, Realistic Award for Women in 2018 for contributions in field of Oncology, Outstanding Abstract award in UAE Cancer Congress in 2014, IDEA fellowship grant in 2005 from American Association Clinical Oncologist, USA, SMS scholarship recipient, Germany in 2005 scholarship by the British High Commissioner, British Chevening/Commonwealth/Nottingham, and an MSc in Oncology in 2002-2003 at Nottingham University. She has presented at more than 50 National and International scientific platforms and has over 50 publications.
Dr. Gowtham has overseen several positions in clinical medicine and innovative research in integrative medicine in collaborations with major research institutes in United states, Australia and India. He ran cutting edge collaborative research projects with World Care Clinical, Harvard Medical School, Madras Medical College and Lupin Pharmaceuticals.
Judith Abeler is a Doctor of Human Medicine and a Specialist in internal medicine in Germany. Since 2013 she has worked clinically in cardiology, gastroenterology, internal medicine, and oncology.